Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. SPRITAM utilizes Aprecia’s proprietary ZipDose® Technology platform, a groundbreaking advance that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid.
The company said that it planned to develop other medications using its 3D platform. Printing the drugs allows layers of medication to be packaged more tightly in precise dosages.
A separate technology developed by the firm, known as ZipDose, makes high-dose medications easier to swallow. Printing the drug meant it could package up to 1,000 milligrams into individual tablets.
The 3D-printed pill dissolves in the same manner as other oral medicines.
More details HERE